Does Dupixent Cause Lymphoma? What the Research Shows

Dupixent (dupilumab) is a widely prescribed biologic medication used to treat eczema, asthma, chronic obstructive pulmonary disease (COPD), and several other inflammatory conditions. Since its approval by the U.S. Food and Drug Administration (FDA) in 2017, millions of patients have used the drug to manage chronic symptoms.

However, recent research has raised concerns about whether Dupixent may increase the risk of a rare form of cancer known as cutaneous T-cell lymphoma (CTCL).

As scientific studies continue to examine the relationship between Dupixent and lymphoma, patients and physicians are asking: Does Dupixent cause lymphoma?

Research Examining the Link Between Dupixent and CTCL

Several studies have investigated whether there is an association between dupilumab and cutaneous T-cell lymphoma. One widely cited study published in 2024 analyzed nearly 20,000 patients treated with dupilumab for atopic dermatitis (eczema). Researchers found that patients taking Dupixent had a 4.59 times higher relative risk of developing CTCL compared to individuals who were not treated with the medication.

The study also found:

• Approximately 62% of CTCL diagnoses occurred within the first year of Dupixent treatment
• About half of the patients diagnosed with CTCL were over age 60
• Many cases involved patients initially treated for eczema symptoms

While researchers emphasize that additional investigation is needed, these findings have raised concerns among dermatologists and patients. Regulators have also begun examining safety data related to the drug. The FDA has indicated it is reviewing potential risks associated with the drug, including reports of CTCL diagnoses among patients using dupilumab.

Because Dupixent remains one of the most widely prescribed biologic medications for eczema and other inflammatory conditions, ongoing evaluation of the drug’s long-term safety is important.

Why CTCL Can Be Difficult to Diagnose

One reason Dupixent-related lymphoma concerns are drawing attention is that CTCL symptoms can resemble eczema, the very condition the drug is designed to treat.

Early symptoms of CTCL may include:

• Red or scaly skin patches
• Persistent itching
• Thickened skin plaques
• Rash-like lesions

Because these symptoms closely resemble eczema or psoriasis, CTCL may initially be misdiagnosed. In some cases, treatment for eczema may continue while the underlying lymphoma progresses.

Patients currently taking Dupixent should not stop treatment without consulting their healthcare provider, but should discuss any unusual skin symptoms or health changes with a medical professional.

Lawsuits Filed Over Dupixent and Lymphoma Risk

As evidence surrounding the potential link between Dupixent and CTCL continues to grow, lawsuits have begun to emerge. In 2025, Childers, Schlueter & Smith filed Georgia’s first Dupixent lawsuit alleging that the manufacturers failed to adequately warn patients and healthcare providers about lymphoma risks.

The lawsuit alleges that drug manufacturers Sanofi and Regeneron were aware of growing reports linking Dupixent to CTCL but failed to update safety warnings.

According to the complaint, researchers and regulators have identified dozens of adverse event reports, case studies, and observational analyses suggesting a possible relationship between dupilumab and lymphoma.

Drug manufacturers maintain that current evidence does not establish a causal relationship between Dupixent and CTCL.

Legal Options for Patients Diagnosed With CTCL

Individuals who were diagnosed with cutaneous T-cell lymphoma after taking Dupixent may be eligible to pursue a dangerous drug lawsuit against the drug’s manufacturers. Eligibility often depends on several factors, including when the medication was taken, when the CTCL diagnosis occurred, and whether medical records support the connection between dupilumab use and the illness. Because every case is different, speaking with an experienced dangerous drug attorney can help determine whether you may qualify to file a Dupixent lawsuit.

Dupixent lawsuits claim the drug’s manufacturers knew or should have known about research and adverse event reports suggesting a potential connection between dupilumab and CTCL but did not update warning labels or prescribing information to reflect those risks.

When pharmaceutical companies fail to provide adequate warnings, patients may unknowingly face serious health issues, so these lawsuits are designed to hold manufacturers accountable and help injured patients recover compensation for the damages they have suffered.

Individuals who developed lymphoma after taking Dupixent may be eligible to pursue compensation for losses such as:

• Medical expenses
• Pain and suffering
• Ongoing medical monitoring and treatment costs

• Lost wages and loss of future earning capacity

In some cases, families who lost a loved one to complications related to CTCL may also be eligible to pursue a wrongful death claim.

At Childers, Schlueter & Smith, our attorneys have decades of experience representing individuals harmed by dangerous pharmaceuticals and defective medical products. Our firm has handled mass tort litigation involving major drug manufacturers, understands the scientific, medical, and legal issues in these cases, and is actively handling Dupixent lymphoma lawsuits.

Because these cases involve complex medical evidence and extensive pharmaceutical industry records, working with an experienced dangerous drug attorney is critical. Our legal team works with medical experts, researchers, and investigators to evaluate claims and determine whether a medication contributed to a patient’s illness.

If you or a loved one were diagnosed with cutaneous T-cell lymphoma after taking Dupixent, our team can review your case, explain your rights, and help determine whether you may be eligible to pursue a Dupixent lawsuit. Contact us online for a free consultation, call 1-800-641-0098, or use our live chat to speak with a member of our legal team.